Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revusiran OLE in TTR Cardiac Amyloidosis
NCT02292186Phase 2Completed
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Oct 2014
- Primary completion
- Feb 2017
- Modality
- Gene Editing, Gene Silencing, Conjugated siRNA
- Countries
- 3
01
Overview
A Phase 2 trial of revusiran in transthyretin amyloid cardiomyopathy (ATTR-CM), sponsored by Alnylam Pharmaceuticals. Started Oct 2014; status: completed.
02
Drugs
revusiran
03
Conditions
transthyretin amyloid cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on NCT02292186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02292186.